Home Featured Page 40

Featured

Latest

“I’m All About the Data”: Dr. Charles Nemeroff on Psychedelics, Ibogaine, and Scientific Rigour

After the Readout: How the Field Is Interpreting Compass’ Phase 3 Psilocybin Data

Q1’26 Psychedelic Drug Development Pipeline: Bullseye Charts

Compass Provides Fuller Phase 3 Picture, MADRS Curves, on Webcast

The Science Behind How Psychedelics Inspire Creative Breakthroughs

Psychedelic Funding Update: Q3 2024

The Hero’s Journey: Finding Your Story in Psychedelic Healing

Illuminating the Hidden Self: Navigating the Jungian Shadow with Psychedelics

Healing Psychedelics: Where Science Meets Spirit

Pα+ Psychedelic Bulletin #175: atai Sells a Third of Compass Stake;...

The Hidden Roots of Australia’s Psychedelic Underground

The Globalization of Ayahuasca, Psychedelic Parenting, and the Power of Ceremony

The Psychedelics Lobby: Tracking Federal Lobbying by Psychedelics Companies and Nonprofits

Tripped: The Connection Between LSD, Nazi Germany, and MKUltra

EDITOR PICKS

“I’m All About the Data”: Dr. Charles Nemeroff on Psychedelics, Ibogaine,...

After the Readout: How the Field Is Interpreting Compass’ Phase 3...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.